Ein Bilderbuch über Hilfe nach traumatischen Erlebnissen für Eltern und Kinder mit Kriegs- und Fluchterfahrung .
Das Trauma-Bilderbuch versucht, ein schweres Thema verständlich darzustellen: Ein Kind erlebt kriegsbedingt eine überwältigende Angstsituation, der „Schatten dieser Angst“ verfo...lgt das Kind noch, wenn die schreckliche Situation bereits eine ferne Vergangenheit geworden sein könnte.
Es kann Kindern, Eltern und deren Unterstützern helfen, die ebenso unsichtbare wie lebenseinschränkende Belastung zu verstehen. Es zeigt auf, was das Kind jetzt braucht: praktische Hilfen im Alltag, tröstende Botschaften der Eltern und evt. den Weg in eine Therapie.
more
Dans la plupart des pays, les services de lutte contre la tuberculose (TB) sont décentralisés jusqu’aux dispensaires
les plus périphériques et souvent au sein même des villages et des quartiers. Par contre, les services
de lutte contre le VIH/Sida sont généralement beaucoup plus centralis...és parce que la diffusion des
soins, notamment de la thérapie antirétrovirale (TARV), n’a commencé qu’assez récemment. De ce fait,
les patients qui ont besoin d’un traitement à la fois contre la tuberculose et le VIH/Sida peuvent être obligés
de se rendre dans deux établissements distincts et ainsi d’avoir à parcourir de longues distances pour
accéder aux soins. L’absence de services intégrés TB/VIH peut provoquer des retards dans le diagnostic
et le traitement, et même se traduire par un mauvais suivi des traitements, voire par des interruptions. Par
ailleurs, les patients ont à supporter la charge financière des frais de déplacement et des autres coûts indirects,
tels que de longs temps d’attente et une perte de revenu
more
Abstract: Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associa...ted risk factors, and describe brief, evidence-based measures that can be used to screen for PTSD and monitor symptom changes over time. In regard to treatment, we highlight commonly used, evidence-based psychotherapies and pharmacotherapies for PTSD. Among psychotherapeutic approaches, evidence-based approaches include cognitive-behavioral therapies (e.g., Prolonged Exposure and Cognitive Processing Therapy) and Eye Movement Desensitization and Reprocessing. A wide variety of pharmacotherapies have received some level of research support for PTSD symptom alleviation, although selective serotonin reuptake inhibitors have the largest evidence base to date.
more
In den letzten Jahren hat die öffentliche Debatte über Kinderschutzfragen zu entscheidenden Veränderungen - sowohl in der Öffentlichkeit wie in der Fachdebatte in Deutschland - geführt. Anfang 2012 trat ein neues Bundeskinderschutzgesetz in Kraft; der Aufarbeitungsprozess nach dem Missbrauchssk...andal, der Deutschland ab Anfang 2010 in einer breiteren öffentlichen Diskussion erschüttert hat, hat mit dem Abschluss der Arbeit der Unabhängigen Beauftragten zur Aufarbeitung des sexüllen Kindesmissbrauchs, der ehemaligen Bundesfamilienministerin Frau Dr. Christine Bergmann, und mit dem Abschlussbericht des Runden Tisches Ende 2011 eine Bestandsaufnahme abgeschlossen und eine Agenda für die weitere Arbeit der Umsetzung aufgestellt. Zu diesen zahlreichen zu bearbeitenden Punkten gehören auch ein hilfreicherer Umgang mit Betroffenen im Gesundheitswesen, eine bessere Diagnostik und Abklärung in Kinderschutzfällen, auch auf der medizinischen Seite. Verzögerungen bei der Implementation von Hilfe, Unterstützungsmaßnahmen und Therapien werden beklagt und Lotsenfunktionen in Bezug auf gesetzliche Ansprüche wie z.B. im Rahmen des Opferentschädigungsrechts werden vorgeschlagen.
more
Prepared as an outcome of ICMR Subcommittee on Soft Tissue Sarcoma and Osteosarcoma | This consensus document on Management of Soft Tissue Sarcoma and Osteosarcoma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular ...markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
more
Prepared as an outcome of ICMR Subcommittee on Tongue Cancer | This Consensus Document on Management of Tongue Cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interw...eaves clinical, biochemical and epidemiological studies.
more
Wenn Patienten nur wenig Deutsch können, ist das Gespräch mit dem Arzt für beide Seiten schwierig. Laienverständliche Informationsmaterialen in verschiedenen Sprachen können die Kommunikation unterstützen und das gegenseitige Verständnis fördern. Vor diesem Hintergrund werden ausgewählte In...formationsblätter in sechs Sprachen übersetzt. Themen u.a. : Antibiotika Resistenzen; Antibiotika Therapie; Asthma; COPD; Depression; Diabetes; Rückenschmerzen;
more
Sangath is a non-governmental, not-for-profit organisation committed to improving health across the life span by empowering existing community resources to provide appropriate physical, psychological and social therapies. Its primary focus areas include child development, adolescent and youth health..., and adult health and chronic disease.
Started in 1996 by seven professionals in Goa, Sangath developed a vision to provide professional healthcare services for developmental disabilities and mental health problems. Today, it is one of the largest NGOs in the state, with more than 100 service providers, two centres in Goa, projects across India, collaborations with leading institutions in the world, and international recognition for its path-breaking research and intervention programmes in the community.
more
Interactive Graphic.This interactive graphic covering our current knowledge of the Ebola virus and the history of disease outbreaks has now been updated with information on convalescent therapies and on drug and vaccine developmen
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
European Scientific Journal March 2015 edition vol.11, No.9 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431
Objective: To describe the clinical, therapeutic and outcome aspects of emergency obstetric care at the University Hospital of Parakou in Benin
Seit zehn Jahren bietet die Forschungsabteilung des ZÜ mit dem Projekt „Ilajnafsy“ Menschen aus dem arabischen Sprachraum, die an Depressionen und Traumafolgestörungen leiden, online psychologische Unterstützung. Der therapeutische Kontakt findet im schriftlichen Austausch über ein programme...igenes, datengeschütztes Webportal statt. Auf diese Weise können auch Menschen in Kriegs- und Krisengebieten Kontakt aufnehmen und eine erste psychologische Unterstützung in Anspruch nehmen.
Der Film erklärt anschaulich, wie eine web-basierte Therapie über Iljanafsy abläuft und welche Menschen das Programm in Anspruch nehmen können. Abrufbar ist der Film auf Englisch, auf Arabisch sowie auf Arabisch mit englischen Untertiteln
more
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report... on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019) presents a decade’s worth of data on drug efficacy and surveillance, as well as recommendations to monitor and protect the efficacy of malaria treatment in the decades to come.
more
These guidelines are based on the 3rd Edition of the WHO Guidelines (Published 2015) World Health Organization’s Guidelines for the treatment of malaria. Additional literature surveys have been undertaken. Factors that were considered in the choice of therapeutic options included effectiveness, sa...fety, and impact on malaria transmission and on the emergence and spread of antimalarial drug resistance. On-going surveillance is critical given the spread of artemisinin resistance in Southeast Asia, although not yet confirmed anywhere in Africa. The guidelines on the treatment of malaria in South Africa aim to facilitate effective, appropriate and timeous treatment of malaria, thereby reducing the burden of this disease in our communities. This is essential to further reduce the malaria case fatality rates currently recorded in South Africa, to decrease malaria transmission and to limit resistance to antimalarial drugs.
more
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il...lness is important.
The living guidance is available in both pdf format (via the ‘Download’ button) and via an online platform in both French and English, and is updated regularly as new evidence emerges.
This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies. This new living guideline is written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures (5, 6). The living guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
more
Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico...rps monoclonaux. Ce nouveau document est rédigé en vue d’accompagner des soins de support optimisés (oSoC) pour les procédures opérationnelles standards appliquees a la MVE (5, 6). Les orientations evolutives presentent des preuves de haute qualité concernant l’efficacite des traitements contre la MVE et les recommandations de l’OMS relatives leur utilisation.
more
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps... in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless, several factors have come together to create a more optimistic scenario. Drug-based research has become more systematic, with increased collaborations between the academic and commercial sectors, often within the framework of not-for-profit consortia. High-throughput screening of compound libraries is being widely applied, and new technical advances are helping to streamline the drug development pipeline. In addition, drug repurposing and optimisation of current treatment regimens, informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide an overview of the current status of Chagas disease drug development, highlight those areas where progress can be expected, and describe how fundamental research is helping to underpin the process.
more
The updates are based on evidence emerging from the: Ongoing monitoring of the disease. Protection that the population already developed against COVID-19 through previous infection or vaccination. Epidemiological situation, availability of diagnostic tests and access to therapeutic options.
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Diskriminierungssensibler Umgang mit Patient*innen ermöglicht allen Menschen gesundheitliche Hilfe aufzusuchen. Im Gesundheitssystem gibt es Menschen, die weniger sichtbar sind als andere. Damit sich Ärzt*innen, Therapeut*innen, Pflegende und andere im Gesundheitssystem
Tätige stärker mit indiv...iduellen Bedürfnissen von Patient*innen auseinandersetzen, gibt dieser
Leitfaden Impulse.
more